started · updated
Samsung Biologics showcases end-to-end ADC service capabilities
Samsung Biologics showcased its end-to-end Antibody-Drug Conjugate (ADC) service capabilities at the World ADC San Diego 2026 conference. The company highlighted its ability to provide integrated services encompassing Contract Research (CRO), Contract Development (CDO), and Contract Manufacturing (CMO) within a single location in Songdo, Incheon.
Having launched its dedicated ADC production facility in March 2025, Samsung Biologics aims to complete its full-cycle service capability by establishing a dedicated drug product (DP) line by 2027. During the event, the company presented technical advancements, including its S-DUAL bispecific antibody platform and its Samsung Organoids platform for patient-derived organoid (PDO) based drug screening.
Company leadership emphasized the goal of meeting diversifying customer demands for new modalities, such as bispecific antibodies and organoids, to secure orders from global pharmaceutical companies.
Entities
Marc Studer · Samsung Biologics · Samsung Organoids · Songdo · World ADC San Diego 2026
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] The company provides end-to-end services including CRO, CDO, and CMO for Antibody-Drug Conjugates (ADC). www.thebionews.net · www.sportalkorea.com · biz.heraldcorp.com
- [● 3 SOURCES] Samsung Biologics launched its dedicated ADC production facility in March 2025. www.thebionews.net · www.sportalkorea.com · biz.heraldcorp.com
- [● 3 SOURCES] The company offers drug screening services using patient-derived organoids (PDO) via Samsung Organoids. www.thebionews.net · www.sportalkorea.com · biz.heraldcorp.com
- [● 3 SOURCES] The company utilizes its S-DUAL bispecific antibody platform for ADC development. www.thebionews.net · www.sportalkorea.com · biz.heraldcorp.com
- [● 3 SOURCES] Samsung Biologics participated in the World ADC San Diego 2026 conference. www.thebionews.net · www.sportalkorea.com · biz.heraldcorp.com
- [● 2 SOURCES] The company plans to establish and operate a dedicated ADC drug product (DP) line by 2027. www.sportalkorea.com · biz.heraldcorp.com